Recent press releases
Pharming announces the presentation of the results of the RUCONEST® Phase II study for prophylaxis of Hereditary Angioedema attacks
FDA Accepts CSL Behring’s Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks
WHO WE ARE
The US HAEA is a non-profit patient advocacy organization dedicated to serving persons with angioedema.
We provide patients and families with a support network and wide range of services.
Executive Vice President
Contact Janet Long